To systematically review the evidence of the association of anticardiolipin antibodies with preeclampsia.
PubMed and LILACS were perused up to June 2009, citations were searched using the ISI Web of Knowledge database, textbooks and reference lists were reviewed, and experts were contacted. Search terms included “antiphospholipid syndrome,” “Hughes' syndrome,” “anticardiolipin antibodies,” “antiphospholipid antibodies,” “anti-cardiolipin,” “preeclampsia,” and “pre-eclampsia.”
Inclusion criteria were: cohorts, case-control, or controlled cross-sectional studies; healthy pregnancy as controls; no autoimmune diseases; immunoglobulin (Ig)G, IgM anticardiolipin antibody of at least 20 units by enzyme-linked immunosorbent assay, or both; and end-point preeclampsia.
Our search generated 68,528 entries and 64 full-text articles were reviewed. Twelve studies were included in the meta-analysis. Pooled odds ratio (OR) for association of anticardiolipin antibodies with preeclampsia was 2.86 (95% confidence interval [CI], 1.37–5.98). Pooled OR for anticardiolipin antibodies and severe preeclampsia was 11.15 (95% CI 2.66–46.75). Funnel plot showed minor asymmetry, and the Egger test was not significant (P=.359). Meta-regression identified study design and size as related to heterogeneity.
Moderate-to-high levels of anticardiolipin antibodies are associated with preeclampsia, but there is insufficient evidence to use anticardiolipin antibodies as predictors of preeclampsia in clinical practice.
There is a positive association of anticardiolipin antibodies with preeclampsia. SUPPLEMENTAL DIGITAL CONTENT IS AVAILABLE IN THE TEXT.
From the Rheumatology Department, São Lucas Hospital, Pontifical Catholic University of Rio Grande do Sul (PUCRS), Porto Alegre, Brazil; Post Graduate Program in Epidemiology, Federal University of Pelotas, Pelotas, Brazil.
For a list of authors and antiphospholipid syndrome experts who were contacted by e-mail about this study, see Appendix 1 online at http://links.lww.com/AOG/A206.
Corresponding author: Aline Defaveri do Prado, Rheumatology Department, São Lucas Hospital PUCRS, Av Ipiranga 6690, room 220, CEP 90610-000 Porto Alegre, Brasil; e-mail: firstname.lastname@example.org.
Financial Disclosure The authors did not report any potential conflicts of interest.